13F Pro quality score
Rank #2,591 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from VOLITIONRX LTD's annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $1.7M | $-23.4M | — |
| FY 2024 | 10-K | $1.2M | $-27.0M | — |
| FY 2023 | 10-K | $775.3K | $-35.7M | — |
| FY 2022 | 10-K | $306.4K | $-30.6M | — |
| FY 2021 | 10-K | $90.0K | $-27.0M | — |
| FY 2020 | 10-K | $13.4K | $-20.4M | — |
VOLITIONRX LTD (VNRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VNRX at 26.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,591 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), VOLITIONRX LTD reports quarterly revenue of $398.7K, net income of $-7.3M, free cash flow of $-5.2M. VNRX trades on the NYSE exchange and files with the SEC under CIK 93314. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VOLITIONRX LTD directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 93314 →